Emmaus Life Sciences, Inc., reports that it sold 25,947 boxes of Endari® in 2020 compared to 24,797 boxes in 2019, an increase of 5%.
Read More
Emmaus Life Sciences, Inc., reported today its financial results for the year ended December 31, 2019 and its restated financial results for the year ended December 31, 2018.
Read More
Emmaus Life Sciences, Inc., announced today that it was notified by the Michigan Department of Health and Human Services (MDHHS) that the prior authorization criteria for Endari® was revised after being reviewed by Michigan’s Medicaid Health Plan Common Formulary Workgroup.
Read More
Emmaus Life Sciences, Inc., announced today the launch of the Endari® Support Program.
Read More
Emmaus Life Sciences, Inc., announced today that the Swiss Agency for Therapeutic Products (Swissmedic) has granted orphan drug status to Endari®.
Read More
Emmaus Life Sciences, Inc., announced today that it has submitted a temporary license application for Endari® to the National Health Regulatory Authority in the Kingdom of Bahrain.
Read More
Emmaus Life Sciences, Inc., announced today revised prescribing information for Endari® to better inform healthcare professionals and sickle cell disease patients.
Read More
Emmaus announced today that it will hold an informational meeting of stockholders at which management will provide an update on recent sales activities and other business and operations.
Read More
Emmaus announced today the submission of an application to the Saudi Food and Drug Authority (SFDA) for Marketing Authorization (MA) for Endari® in the Kingdom of Saudi Arabia.
Read More
Interim Analysis Indicates Decreased Number of Diverticula and Healthy Tissue
Read More
Emmaus provided today additional operational updates for the year ended December 31, 2019 as well as operational updates for the quarters ended March 31 and June 30, 2020
Read More
Emmaus announced today that the EMA issued scientific advice to Emmaus regarding the clinical development pathway for Xyndari™ for the treatment of sickle cell disease.
Read More
Emmaus announced today the opening of its regional office in Dubai. The Dubai office will be utilized to enhance Emmaus’ relationships with clinicians and patient groups at major hospitals and other government-sponsored health care facilities in communities throughout the Middle East and North Africa (MENA) region.
Read More
Emmaus Life Sciences, Inc. is pleased to announce that it has engaged Partner International to lead the out-licensing activity for Emmaus’ prescription grade L-glutamine (PGLG) oral powder for use in the treatment of diverticulosis.
Read More
Emmaus Life Sciences, Inc. announced today that it was issued a license from the Israeli Ministry of Health on June 17, 2020 granting marketing authorization for the commercial distribution and sale of Endari® in Israel.
Read More
Patented Topical Ointment for Treating Skin Ulceration in Sickle Cell Disease and other Indications
Read More
We stand in solidarity with all those who have been unfairly targeted by racial injustice and racism in our world today. We march with those who strive towards a better future, and as the late Martin Luther King Jr. once said, we have this hope that we can create a world in which people are not judged by the color of their skin but the content of their character
Read More
Emmaus Life Sciences, Inc., provided today operational updates in advance of the filing of its 10-K for the year ended December 31, 2019 and its 10-Q for the first quarter of 2020.
Read More
Emmaus announced today that APCER Life Sciences (APCER) has confirmed the safety profile of Endari®, Emmaus’ prescription grade L-glutamine oral powder for the treatment of sickle cell disease.
Read More
Emmaus announced today that the SFDA (Saudi Food & Drug Authority) has accepted its request for priority review of Endari®.
Read More
Within the overall SCD community, Emmaus is working in coordination with the Sickle Cell Disease Association of America and other organizations to educate and communicate with the SCD community during this challenging time.
Read More
Emmaus Life Sciences, Inc., announced today the execution of a purchase agreement for up to $25 million of common stock with Lincoln Park Capital Fund, LLC (“LPC”), a long-only Chicago-based institutional investor.
Read More
Company Reports Highest Gross Monthly Sales of 2019 and
Total Gross Sales of $7.8 Million in the Fourth Quarter.
Read More
Decreased Size of Diverticula, Indications of Healing and Normalization of Bowel Movements Observed in the Initial Patient
Read More
To the Detriment of the Sickle Cell Disease Community, the Draft Report Does Not Accurately Reflect or Interpret the Original Clinical Data and Related Efficacy and Safety of
L-Glutamine Validated and Approved by the FDA
Read More
Implementing the Program in Collaboration with US Bioservices, an AmerisourceBergen Specialty Pharmacy, Will Drive Increased Compliance with Clinicians Recommended Treatment Programs and Provides an Unprecedented Resource for Patients with Sickle Cell Disease
Read More
Emmaus Life Sciences, Inc. today reported that it received the initial purchase order relating to taiba Healthcare’s early access program for Endari®.
Read More
Emmaus Life Sciences, Inc., today reported that it expects to receive shortly the initial purchase orders relating to taiba Healthcare’s early access program for Endari® (L-glutamine oral powder) in certain countries in the Middle East and North Africa (MENA) region.
Read More
Net Revenues Increased 25% Year-Over-Year,
Company Opens and Expands Class of Trade with Community Hematologists and Correctional Facilities
Read More
Vivozon, Inc. executes a stock purchase agreement for a total of $2.4 million.
Read More
Company Reports Highest Gross Sales Month of 2019 and Total Gross Sales of $7.0 Achieved in the Third Quarter.
Read More
Issuance by the Indian Patent Office Further Bolsters Emmaus’ International Intellectual Property Portfolio
Read More
Emmaus approved to have its common stock trade on the OTCQB marketplace.
Read More
Summary review of the clinical trials and efficacy findings for Endari.
Read More
Emmaus Life Sciences to withdraw MAA
Read More
Campaign spokesperson Solomon Wilcots will be joined by fellow NFL veteran player Jocelyn Borgella of the Detroit Lions, Dr. Ahmar Zaidi and Dr. Michael Callaghan of the Children’s Hospital of Michigan and the Sickle Cell Disease Association of America Michigan Chapter (SCDAAMI)
Read More
Company Committed to Listing on Major Exchange
Read More
Related patents granted in the United States, Japan, Australia, Mexico, China, Indonesia, South Korea and Russia; Patents pending in Brazil and other countries
Read More
Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced today the addition of Oncology Supply, a part of Amerisource Bergen, as a distributor of its signature product, Endari® (L-glutamine oral powder).
Read More
Campaign spokesperson Solomon Wilcots will be joined by fellow NFL Veteran Antonio "Dayla" Brown, the Advancing Sickle Cell Advocacy Project (ASAP) and the Foundation for Sickle Cell Disease Research (FSCDR)
Read More
Net Revenues Increase 128% Year-Over-Year, as FDA-Approved Treatment for Sickle Cell Disease Rolls Out
Read More
Company to Announce Second Quarter Financial Results Next Week
Read More
Company to Appeal Nasdaq Staff’s Determination
Read More
Campaign spokesperson Solomon Wilcots and Senior Vice President of Research and Development for Emmaus, Charles Stark, Pharm.D., will lead an informative presentation at the event’s Young Adult Reception.
Read More
Emmaus to Appeal Nasdaq Staff’s Determination
Read More
Emmaus Shares Expected to Begin Trading Tomorrow on Nasdaq Under Ticker Symbol “EMMA”
Read More
The proposed merger and spin-off transactions were approved by their respective stockholders at the special stockholder meetings held yesterday, July 9, 2019
Read More
Merger and Spin-off Transaction on Track to Close by End of July
New Spin-Off Record Date Set for July 15, 2019
Read More
Study will evaluate change in number and size of colonic diverticula and assess safety.
Read More
Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced today the hiring of Michael Schwarz as its new Product Manager for Endari®
Read More
Emmaus to use its pharmaceutical-grade L-glutamine ("PGLG") in a clinical study to determine its efficacy in lowering blood sugar in patients with type II diabetes.
Read More
Emmaus Life Sciences, Inc., a specialty pharmaceutical and
regenerative medicine company, today issued the following statement in response to an announcement
issued October 9, 2012, by AFH Holding & Advisory, LLC.
Read More
TORRANCE, Calif., September 13, 2012 –In conjunction with Sickle Cell Awareness Month, Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, announced that its U.S. Phase III clinical trial to study L-Glutamine as a treatment for sickle cell disease is nearing target enrollment completion, with investigation now underway at more than 30 clinical study sites throughout the U.S.
Read More
Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, and subsidiary of Emmaus Life Sciences, Inc., today announced that the European Commission (EC) has granted Orphan Medicinal Product designation for the company’s investigational drug Levoglutamide (L-glutamine) for the treatment of sickle cell disease.
Read More
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).
Read More